NEW YORK, April 25 (Reuters) - Vertex Pharmaceuticals Inc’s experimental hepatitis C drug, telaprevir, proved significantly better than standard therapy in knocking out the virus in patients for whom prior treatments failed, according to results of a clinical study.
